Multi-center MRD Registry for Inflammatory Breast Cancer

Launched by M.D. ANDERSON CANCER CENTER · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding inflammatory breast cancer (IBC) by collecting important information from participants. Specifically, the study will gather data from individuals who have been diagnosed with stage III or IV IBC and may have had a specific blood test called Signatera. This test helps detect tiny amounts of cancer that may remain in the body after treatment. The goal is to learn more about how these tests can help guide future treatment decisions, especially for those planning to have surgery.

To be eligible for this trial, participants must be at least 18 years old, able to speak and understand English, and within eight months of their IBC diagnosis. They should have had at least one blood test for Signatera and should not have undergone breast surgery for their cancer yet. While the study is not currently recruiting participants, it aims to provide valuable insights into IBC and improve care for future patients. Participants can expect to contribute to a growing database that will help researchers better understand this type of breast cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female or males ≥18 years of age with the ability to understand and sign a written
• • Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
• • Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
• • Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
• • Participants must be English-speaking.
• Exclusion Criteria:
• • -